Research programme: therapeutics - BioStem Technologies/CCM Pharma Solutions

Drug Profile

Research programme: therapeutics - BioStem Technologies/CCM Pharma Solutions

Alternative Names: BSEM18-120; BSEM18-125; BSEM18-130; BSEM18-135

Latest Information Update: 30 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioStem Technologies; CCM Pharma Solutions
  • Class Cardiovascular therapies; Neuroprotectants
  • Mechanism of Action ACE inhibitors; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cardiovascular disorders; CNS disorders; Hypertension; Metabolic disorders; Schizophrenia

Most Recent Events

  • 19 Jul 2018 Nesvik Pharmaceuticals completes the asset purchase of multiple new drug compounds from CCM Pharma Solutions
  • 11 Jul 2018 Preclinical trials in Hypertension in Malaysia, USA (PO) (BioStem Technologies, July 2018)
  • 11 Jul 2018 Preclinical trials in Schizophrenia in Malaysia, USA (PO) (BioStem Technologies, July 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top